

Daniel P. McCauliffe, M.D.
Curriculum Vitae

Education / Postgraduate Training:

1970-1973 Granville High School, Granville, NY
Valedictorian

1973-1977 Rensselaer Polytechnic Institute, Troy, NY
Graduated with Highest Academic Honors
BS-Biology, 1977

1977-1981 Albany Medical College, Albany, NY
Dean's Letter of Commendation for Academic Excellence
MD, 1981

1981-1984 Internal Medicine Residency
Wright-Patterson AFB Medical Center, Dayton, OH

1987-1991 Dermatology Residency and Immunodermatology Research Fellowship
University of Texas Southwestern Medical Center, Dallas, TX

Military Service:

1984-1986 Chief of Medicine, Director of Medical Education, Director of
Emergency Care Services, USAF Hospital, Grand Forks AFB, ND

1986-1987 Staff Internist, USAF Medical Center, Scott AFB, IL

Academic Positions:

1985-1986 Clinical Assistant Professor of Medicine
University of North Dakota Medical School, Grand Forks, ND

1990-1991 Research Assistant Professor of Dermatology
University of Texas Southwestern Medical Center, Dallas, TX

1991-1996 Assistant Professor of Dermatology
University of North Carolina, Chapel Hill, NC

1996-2000 Associate Professor of Dermatology
University of North Carolina, Chapel Hill, NC

2004-2020 Adjunct Clinical Professor of Dermatology
University of North Carolina, Chapel Hill, NC

Board Certifications:

National Board of Medical Examiners
American Board of Internal Medicine
American Board of Dermatology

Medical Licensure:

North Carolina, 1991-present
Vermont, 2000-present

Professional Organizations:

American Academy of Dermatology, 1991 - present
Dermatology Foundation Leaders Society, 1997 - 1999, 2005-12

Professional Awards:

US Air Force Health Professional Scholarship (1978-81)
Upjohn Research Award, recognition for outstanding research in dermatology (1988)
Young Investigator Award, Clinical Dermatology (1990)
Dermatology Foundation Career Development Award (1990-2)
University of North Carolina Junior Faculty Development Award (1992)
National Institutes of Health FIRST Award (1993-7)
National Institutes of Health R01 Award (1995-8)

Professional Clinical Activities:

Medical dermatology including the evaluation and treatment of pediatric and adult diseases of the skin, hair and nails

Surgical dermatology including surgical excisions, laser treatment and repairs of skin lesions and defects

Aesthetic dermatology including botulinum toxin (Botox, Dysport) for medical and cosmetic purposes; sclerotherapy; vascular laser treatment of cutaneous vascular lesions; laser skin resurfacing; collagen, calcium hydroxylapatite (Radiesse) and hyaluronic acid (Restylane, Juvederm, Perlane) treatments; tumescent liposuction; and intense pulse light (IPL) therapy for photo-rejuvenation, permanent hair reduction, and leg vein treatment.

Attending and consultant work on hospitalized patients with cutaneous disease

Teaching of medical students, dermatology residents and residents in other specialties, and primary care physicians

Past Director of the University of North Carolina Dermatology Clinics, Founder and Current Director of the Rutland Skin Center (www.RutlandSkin.com)

International, National & Regional Lectures given by Dr. McCauliffe:
(excludes local lectures)

1991 American Academy of Dermatology, Dallas, TX; Introductory Allergy and Immunology Course: Cutaneous Lupus Erythematosus.

1992 American Academy of Dermatology, San Francisco, CA; Introductory Allergy and Immunology Course.

World Congress of Dermatology, New York, NY; Lupus Erythematosus Symposium. Area Health Education Center (AHEC), Ashboro, NC; Cutaneous Lupus Erythematosus.

AHEC, Charlotte, NC; Cutaneous Lupus Erythematosus.

1993 American Academy of Dermatology, Washington, DC; Practical Management of Patients with Collagen Vascular Disease Symposium.

AHEC, Charlotte, NC; Molecular dermatology.

1994 Invited Guest Speaker - 4th Annual UNC/Duke Rheumatology Update, Research Triangle Park, NC; Cutaneous Lupus Erythematosus.

AHEC, Charlotte, NC; Ro/SS-A Autoantibodies.

Invited Guest Speaker - Japanese Society for Investigative Dermatology, National Meeting, Osaka, Japan; Similarities in Autoantibody Response in Annular Erythema of Sjogren's Syndrome and Subacute Cutaneous Lupus Erythematosus.

1996 Southeastern Consortium for Dermatology, Chapel Hill, NC; Patient Case Presentations.

AHEC, Charlotte, NC; Teledermatology, Interesting Dermatology Cases.

1997 AHEC, Burlington, NC; What's New in Dermatology.

AHEC, High Point, NC; Cutaneous Manifestations of Systemic Disease.

American Academy of Dermatology Meeting, Washington D.C.; Cutaneous Disease Associations with Ro/SS-A Autoantibodies in Adults (Rheumatology Symposium).

North Carolina Dermatology Association Annual Meeting, Pinehurst, NC; Practical Value of ANA and Related Tests in the Evaluation of Collagen Vascular Diseases.

1998 American Academy of Dermatology, Orlando, FL; Update in Collagen Vascular Diseases; Autoantibody Testing - A Practical Approach for Dermatologists.

Invited Guest Speaker - International Neonatal Lupus Erythematosus Symposium, Milan, Italy; Conventional Ro/SS-A Serologic Assays Fail to Detect Anti-52 kD Ro/SS-A Autoantibodies; Cutaneous Diseases Associated With the Ro/SS-A Autoimmune Response.

AHEC, Henderson, NC; Dermatology Update.

Invited Guest Speaker - Pan-American Congress of Rheumatology, Montreal, Canada; Management of Refractory Cutaneous Lupus Erythematosus.

Invited Guest Speaker - Medicine Grand Rounds, Mary Imogene Bassett Medical Center, Cooperstown, NY; Practical Value of ANA and Related Tests in the Evaluation of Collagen Vascular Disorders.

Invited Guest Speaker - Dermatology Symposium, NC State University – College of Veterinary Medicine; Cutaneous Lupus Erythematosus.

Invited Guest Speaker - New Zealand Dermatology Society Meeting, Port Vila, Vanuatu; Cutaneous Lupus Erythematosus; Antinuclear Antibody Testing-A Dermatologist's Perspective; Dermatomyositis; Neonatal Lupus Erythematosus and Other Ro/SS-A Autoantibody-Associated Cutaneous Disorders.

1999 Invited Guest Speaker - Grand Rounds, St. Paul Medical Center, Dallas, TX: Diagnosing and Managing Cutaneous Lupus Erythematosus.

American Academy of Dermatology, New Orleans, LA; Update in Collagen Vascular Diseases; ANA Testing - A Practical Approach for Dermatologists; Rheumatology Symposium-Cutaneous diseases associated with anti-Ro/SS-A Autoantibodies.

Invited Guest Speaker - CAPS 1999 Continuing Education Seminar, Durham, NC: Dermatology Update; Fundamental Skin Disease Assessment.

Invited Speaker - North Carolina Dermatology Association Annual Meeting, Research Triangle Park, NC: Dermatologic uses of Botulinum Toxin (Botox).

2000 Invited Guest Speaker - Department of Dermatology, University of Iowa, Iowa City, IA: Dermatomyositis, Diagnosis and Management; Practical Value of ANA Testing.

American Academy of Dermatology, San Francisco, CA: Internal Medicine Course - Lupus Erythematosus and Scleroderma; Rheumatology Symposium - Autoantibody Detection Assays: What to Order; Cutaneous Lupus Erythematosus.

2001 American Academy of Dermatology, Washington, DC: Internal Medicine Course - Lupus Erythematosus and Scleroderma.

Duke University Medical Center, Durham, NC: Cutaneous Lupus Erythematosus.

2002 American Academy of Dermatology, New Orleans, LA: Internal Medicine Course - Lupus Erythematosus and Scleroderma.

2003 University of North Carolina, Chapel Hill, NC: Cutaneous Lupus Erythematosus; Transition from Academia to Private Practice.

Invited Guest Speaker - Fun & CME by the Sea Meeting, Bald Head Island, NC: Update and Review on ANA testing.

2004 University of North Carolina, Chapel Hill, NC: Antinuclear Antibody Testing from a Dermatologist's Perspective; Cutaneous Lupus Erythematosus; Neonatal Lupus Erythematosus and other Ro/SS-A Autoantibody Associated Disorders; Dermatomyositis; Transition from Academia to Private Practice.

2005 University of North Carolina, Chapel Hill, NC: Cosmetic Dermatology Treatments for Restoring and Maintaining a Healthy Looking Face (Topical, Botox, Filler, Thread-Lift, Laser, IPL, LED, Infrared, Radiofrequency and Nitrogen Plasma Resurfacing treatments); ANA Testing; Cutaneous Lupus Erythematosus.

Invited Guest Speaker – Medical Grand Rounds, Baystate Medical Center, Springfield, MA; Cutaneous Lupus Erythematosus: So much more than a pretty butterfly rash!

2006 University of North Carolina, Chapel Hill, NC: Cutaneous Lupus Erythematosus; Transition from Academia to Private Practice.

2007 Invited Guest Speaker - North Carolina Dermatology Association Annual Meeting, Pinehurst, NC: Update on Cutaneous Lupus Erythematosus and Dermatomyositis. University of North Carolina, Chapel Hill, NC: Cutaneous Lupus Erythematosus; Dermatomyositis. Duke University, Durham, NC-Grand Rounds Lecture: Neonatal Lupus Erythematosus and other Ro/SS-A associated cutaneous disorders

2008 University of North Carolina, Chapel Hill, NC: Cutaneous Lupus Erythematosus

2011 University of North Carolina, Chapel Hill, NC: Cutaneous Lupus Erythematosus

2012 University of North Carolina, Chapel Hill, NC: Dermatomyositis

2013 University of North Carolina, Chapel Hill, NC: Neonatal Lupus Erythematosus and other Ro/SS-A associated cutaneous disorders

Dr. McCauliffe has been a reviewer of articles submitted for publication to the following journals:

Archives of Dermatology
Arthritis and Rheumatism
Clinical and Experimental Immunology
Journal of the American Academy of Dermatology
Journal of Clinical Investigation
Journal of Immunology
Journal of Investigative Dermatology
Journal of Musculoskeletal Medicine
Journal of Pediatrics
Journal of Rheumatology
Lancet
Lupus
New England Journal of Medicine
Scandinavian Journal of Rheumatology

Publications:

McCauliffe DP, Lieu TS, Sontheimer RD. An enzyme-linked immunosorbent assay (ELISA) inhibition technique for quantifying Ro/SS-A antigen in skin and other types of human tissue. Clin Res 36:673A, 1988.

McCauliffe DP, Lieu TS, Sanz I, Hanke J, Newkirk M, Sontheimer RD, Capra JD. Structural, immunological and molecular genetic studies of the Ro/SS-A

(Ro) polypeptide. Clin Res 36:377A, 1988.

McCauliffe DP, Lieu T-S, Sanz I, Hanke J, Newkirk M, Capra JD, Sontheimer RD. Immunological and molecular genetic studies of the Ro/SS-A polypeptide. Clin Res 37:79A, 1989.

Lieu T-S, McCauliffe DP, Capra JD, Sontheimer RD. Structure and epitope study of human Ro/SS-A antigen. FASEB J 3:A491, 1989.

Lieu T-S, McCauliffe DP, Arnett FC, Lee LA, Deng J-S, Capra JD, Sontheimer RD. Epitope mapping of the human Wil-2 cell Ro/SS-A autoantigenic polypeptide. Clin Res 37:662A, 1989.

McCauliffe DP, Lieu T-S, Capra JD, Sontheimer RD. The genomic configuration of a human Ro/SS-A gene. Clin Res 37:758A, 1989.

McCauliffe DP, Lux FA, Lieu TS, Sanz I, Hanke J, Newkirk M, Siciliano MJ, Sontheimer RD and Capra JD. 1989. Ro/SS-A and the pathogenic significance of its antibodies. J Autoimmunity 2:375-81, 1989.

Lieu TS, McCauliffe DP, Newkirk MM, Arnett FC, Lee LA, Deng JS, Capra JD, Sontheimer RD: A major autoepitope is present on the amino terminus of the human Ro/SS-A polypeptide. J Autoimmunity 2:367-374, 1989.

McCauliffe DP, Lux FA, Lieu TS, Sanz I, Hanke J, Newkirk MM, Bachinski LL, Itoh Y, Siciliano MJ, Reichlin M, Sontheimer RD, Capra JD: Molecular cloning, expression and chromosome 19 localization of a human Ro/SS-A autoantigen. J Clin Invest 85:1379-91, 1990.

McCauliffe DP, Lieu TS, Michalak M, Sontheimer RD, Capra JD: A human Ro/SS-A autoantigen is the homologue of calreticulin and is highly homologous with onchocercal Ral-1 antigen and an aplysia memory molecule. J Clin Invest 86:332-335, 1990.

Sontheimer RD, McCauliffe DP. Pathogenesis of anti-Ro/SS-A autoantibody-associated cutaneous lupus erythematosus. Dermatology Clinics 8:751-758, 1990.

Lieu T-S, McCauliffe DP, Volpe P, Alderson-Lang BH, Michalak M, Capra JD, Sontheimer RD: Structural and Functional Homology Between a Human Ro/SS-A (Ro) Autoantigen and the Calcium-binding Protein (CBP), Calreticulin (CR). Clin Res 38:408A, 1990.

McCauliffe DP, Lieu T-S, Kennedy T, Sontheimer RD, Capra JD: A Human Ro/SS-A (Ro) Autoantigen is the Human Homologue of Murine Calreticulin, Onchocercal Ral-1 Antigen, and Aplysia Protein 407. Clin Res 38:631A, 1990.

Zappi E, McCauliffe DP, Sontheimer RD and Capra JD: Cloning and Sequencing of the Drosophila Homologue of a Human Ro/SS-A (Ro) Autoantigen. Clin Res 38:633A, 1990.

Lux FA, McCauliffe DP, Buttner DW, Capra JD, Sontheimer RD, Lieu T-S: Antibodies (Abs) to *Onchocerca Volvulus* Cross-React with a Human Ro/SS-A (Ro) Autoantigen (Aag). *Clin Res* 38:626A, 1990.

Lieu T-S, McCauliffe DP, Lee LA, Norris DN, Capra JD, Sontheimer RD: Variant Epitope Binding Protein (EBP) of Drug-Induced Ro/SS-A Autoantibodies (A-Ro). *Clin Res* 38:631A, 1990.

McCauliffe DP, Sontheimer RD, Capra JD: Characterization of the human 46 kD Ro/SS-A autoantigen promoter region. *Arthritis Rheum* 33S:C131, 1990.

Sontheimer RD, McCauliffe DP, Michalak M, Capra JD, Lieu TS: Cytoplasmic localization of a calcium-binding 46 kD human Ro/SS-A antigen. *Arthritis Rheum*, 33S:B15, 1990.

McCauliffe DP, Yang YS, Sontheimer RD, Capra JD. Characterization of the promoter region of human calreticulin (the 46 kD Ro/SS-A autoantigen). *J Invest Dermatol* 96:538, 1991.

Lieu TS, Zappi EG, McCauliffe DP, Haseman CA, Capra JD, Sontheimer RD. Frequency of antibodies to human calreticulin in precipitating Ro/SS-A autoantibody-positive sera. *J Invest Dermatol* 96:572, 1991.

Zappi EG, McCauliffe DP, Haseman CA, Lieu TS, Sontheimer RD, Capra JD. Expression of the human 46 kD Ro/SS-A autoantigen (calreticulin) as a recombinant protein. *J Invest Dermatol* 96:561, 1991.

Sontheimer RD, Lieu T-S, McCauliffe DP. Molecular Characterization of the Ro/SS-A autoimmune response. *Seminars in Dermatology* 10:199-205, 1991.

McCauliffe DP and Poitras K. Aspartame-induced lobular panniculitis. *J Am Acad Dermatol* 24:298-300, 1991.

McCauliffe, DP, Gardner D. Ro/SS-A autoantibodies reactivity with recombinant 60, 52 and 46 kD fusion proteins. *J Invest Dermatol* 98:630, 1992.

Sontheimer RD, McCauliffe DP, Wilson JL, Capra JD. Transcriptional regulation of human calreticulin. *J Invest Dermatol* 98:628, 1992.

McCauliffe DP, Yang YS, Wilson J, Sontheimer RD, Capra JD. The 5' flanking region of the human calreticulin gene is highly homologous with the human GRP78, GRP94 and protein disulfide isomerase promoters. *J Biol Chem* 267:2557-2562, 1992.

McCauliffe DP, Sontheimer RD. Subacute cutaneous lupus erythematosus. In: Wallace DJ and Hahn BH, editors. *Dubois' Lupus Erythematosus*. Philadelphia, Lea & Febiger, 302-309, 1992.

Sontheimer RD, McCauliffe DP, Zappi E, Targoff IN. The fine specificity of rheumatic disease-associated autoantibodies. *Advances in Dermatology* 7:3-52, 1992. Chicago: Year Book Medical Publishers, Inc.

Black AA, McCauliffe DP, Sontheimer RD. Prevalence of acne rosacea in a rheumatic skin disease subspecialty clinic. *Lupus* 1:229-237, 1992.

Lux FA, McCauliffe DP, Buttner DW, Capra JD, Sontheimer RD, Lieu TS. Serologic cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the Ral-1 antigen of *Onchocerca volvulus*. *J Clin Invest* 89:1945-1951, 1992.

McCauliffe DP, Sontheimer RD. Molecular studies of the Ro/SS-A autoantigens. Pages 798-804 In: *Dermatology Progress & Perspectives*; eds: Burgdorf WHC and Katz SI. Parthenon Publishing Group, Inc., Pearl River, New York, 1992.

Lucas L, Yin H, McCauliffe DP. 52 and 60 kD Ro/SS-A autoantigens are expressed by human keratinocytes and are reactive with subacute cutaneous and neonatal lupus erythematosus sera. *J Invest Dermatol* 100:575, 1993.

Lowen L, McCauliffe DP. The 52 kD Ro/SS-A autoantigen binds DNA with high affinity and is a member of a novel family of zinc finger proteins. *J Invest Dermatol* 100:553, 1993.

McCauliffe DP, Sontheimer RD. Molecular characterization of the Ro/SS-A autoantigens. *J Invest Dermatol* 100:73S-79S, 1993.

McCauliffe DP and Sontheimer RD. Dermatologic Manifestations of Rheumatic Disorders. *Primary Care* 20:925-941, 1993.

Cornelius PB, McCauliffe DP. Detection of Ro/SS-A autoantibodies in dermatomyositis sera. *J Invest Dermatol* 102:635, 1994.

McCauliffe DP, Yin H, Wang L, Lucas L. Subacute cutaneous and neonatal lupus erythematosus sera react with multiple epitopes on the 52 and 60 kD Ro/SS-A autoantigens. *J Invest Dermatol* 102:635, 1994.

McCauliffe DP, Lupus erythematosus-specific cutaneous disease. *Keio J Med* 43:225, 1994.

McCauliffe DP, Yin Y, Wang L, Lucas L. Autoimmune sera react with multiple epitopes on recombinant 52 and 60 kD Ro/SS-A proteins. *J Rheumatol* 21:1073-1080, 1994.

Satoh M, Langdon JJ, Chou CH, McCauliffe DP, Treadwell EL, Ogasawara T, Hirakata M, Suwa A, Cohen PL, Eisenberg RA, Reeves WH. Characterization of the Su antigen, a macromolecular complex of 100/102 and 200-kDa proteins recognized by autoantibodies in systemic rheumatic diseases. *Clin Immunol Immunopathol* 73:132-141, 1994.

McCauliffe, DP. The autoantibodies of neonatal lupus erythematosus. *J Invest Dermatol* 102: 827, 1994.

Yell JA, Wang L, Yin H, McCauliffe DP. The location of the 60 and 52 kD Ro (SS-A) antigens in human keratinocytes. *J Invest Dermatol* 104:641,1995.

McCauliffe DP, Guest PJ, Folds JD. Cytoplasmic fluorescence on routine ANA testing is frequently associated with anti-60 kD Ro/SS-A autoantibodies. *J Invest Dermatol* 104:679, 1995.

McCauliffe DP. Neonatal Lupus Erythematosus: A transplacentally acquired autoimmune disorder. *Semin Dermatol* 14: 47-53, 1995.

McCauliffe DP, Wang L, Small D. A recombinant 52 kD Ro(SS-A) ELISA detects autoantibodies in primary Sjogren's syndrome sera that go undetected by conventional serologic assays. *Arthritis Rheum* 39:S181, 1996.

Yell, JA, Wang, L, Yin H, McCauliffe DP. 52 and 60 kD Ro/SS-A autoantigens have disparate intracellular locations in human keratinocytes. *Arthritis Rheum* 39:S181, 1996.

McCauliffe DP, Faircloth E, Wang L, Hashimoto T, Hoshino Y, Nishikawa T. Similar Ro/SS-A autoantibody epitope and titer responses in annular erythema of Sjogren's syndrome and subacute cutaneous lupus erythematosus. *Arch Dermatol* 32:528-531, 1996.

Yell JA, Wang L, Yin H, McCauliffe DP. Disparate locations of the 52 and 60 kD Ro/SS-A antigens in cultured human keratinocytes. *J Invest Dermatol* 107:622-626, 1996.

McCauliffe, DP. Antibody penetration into the cells of mice and men. *J Invest Dermatol* 107:3-4, 1996.

McCauliffe DP, Sontheimer RD. Cutaneous lupus erythematosus. Pages 67-82. In: *The Clinical Management of Systemic Lupus Erythematosus*, Ed: Schur PH. Lippincott-Raven Publishers, New York, 1996.

McCauliffe DP, Wang L, Satoh M, Reeves W, Small D. Anti-52 kD Ro(SS-A) autoantibodies go undetected by conventional Ro Serologic assays. *J Invest Dermatol* 108: 640, 1997.

McCauliffe DP, Wang L, Satoh M, Reeves WH, Small D. A recombinant 52 kD Ro(SS-A) ELISA detects autoantibodies in Sjogren's Syndrome sera that go undetected by conventional serologic assays. *J Rheumatol* 24:860-6, 1997.

McCauliffe DP. Cutaneous associations of anti-Ro/SS-A autoantibody production in adults. *Lupus* 6:158-166, 1997.

Skidmore RA, Davis DA, Woosley JT and McCauliffe DP. Massive dystrophic

calcinosis cutis secondary to chronic needle trauma. *Cutis* 60:259-62, 1997.

McCauliffe DP. Distinguishing subacute cutaneous from other types of lupus erythematosus. *Lancet* 351:1527-8, 1998.

Franceschini F, Calzavara-Pinton P, Quinzanini M, Cavazzana I, Bettoni L, Zane C, Facchetti F, Airò P, McCauliffe DP, Cattaneo R. Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. *Lupus* 8:215-219, 1999.

Gahli F, Groben P, McCauliffe DP. Panniculitis in juvenile dermatomyositis. *Pediatr Dermatol*, 16:270-2, 1999.

Gahli F, Stein L, McCauliffe DP. Rediscovery of gingival telangiectasias as a cutaneous marker for juvenile dermatomyositis. *Arch Dermatol* 135:1370-74, 1999.

Sweeny AL, McCauliffe DP. 52 Ro/SS-A protein resides along cytokeratin filaments in epithelial cells. *J Invest Dermatol* 114:856, 2000.

Lopez M, Wozniacka A, McCauliffe DP. 52 Ro/SS-A protein resides along cytokeratins and other intermediate filaments. *Arthritis Rheum* 2000.

Jewell M, McCauliffe DP. Cutaneous lupus erythematosus patients that smoke are less responsive to antimalarial treatment. *J Am Acad Dermatol* 42:983-7, 2000.

McCauliffe DP. Neonatal Lupus Erythematosus, In: *Textbook of Paediatric Dermatology*, edited by Harper J, Oranje A, and Prose N. Blackwell Science Ltd, Oxford. Pages 111-6, 2001.

Morrell DS, Ghali FE, Stahr BJ, McCauliffe DP. Eccrine angiomatous hamartoma: A report of symmetric and painful lesions of the wrists. *Pediatr Dermatol* 18:117-9, 2001.

McCauliffe DP. Cutaneous lupus erythematosus. *Semin Cutan Med Surg* 20:14-26, 2001.

Reeves WH, Satoh M, McCauliffe DP. Autoantibody testing by Non-Fluorescein Isothiocyanate (FITC) Methods. In: Rose NR, Hamilton RG and Detrick B, editors. *Manual of Clinical Laboratory Immunology*, 6th edition. ASM Press, 2002.

McCauliffe DP, Sontheimer RD. Cutaneous lupus erythematosus. Pages 573-618. In: Wallace DJ and Hahn BH, editors. *Dubois' Lupus Erythematosus*, 5th edition. Philadelphia. Lippincott, Williams & Wilkins, 2002.

Wozniacka A, Carter A, McCauliffe DP. Mechanisms by which antimalarials may provide therapeutic benefit in cutaneous lupus erythematosus. *Lupus* 11:71-81, 2002.

McCauliffe DP, Wozniacka A. 52 kD Ro/SS-A localizes to punctate structures in the cytoplasm of epithelial cells. *Cell Mol Biol Lett* 8:133-40, 2003.

Wozniacka A, Robak E, McCauliffe DP, Sysa-Jedrzejowska A. Pneumocystis carinii mimicking neonatal lupus erythematosus-related pneumonitis. *Pediatric Dermatology* 20:524-8, 2003.

Wozniacka A, Langer K, McCauliffe DP, Sysa-Jedrzejowska A, Langer M. Quantitative evaluation of 52 kD Ro/SS-A intracellular distribution in keratinocytes exposed to UVB radiation. *Optica Applicata* 34:77-85, 2004.

Albrecht J, Berlin JA, Braverman IM, Callen JA, Costner MI, Dutz J, Fivenson D, JL Jorizzo JL, Lee LA, McCauliffe DP, Sontheimer RD, Werth VP. Dermatology position paper on the revision of the 1982 ACR criteria for systemic lupus erythematosus. *Lupus* 13: 1-11, 2004.

Wozniacka A, McCauliffe DP. Optimal use of antimalarials in treating cutaneous lupus erythematosus. *Am J Clin Dermatol.* 6:1-11, 2005.

McCauliffe DP. Neonatal Lupus Erythematosus, In: Textbook of Paediatric Dermatology, second edition, edited by Harper J, Oranje A, and Prose N. Blackwell Science Ltd, Oxford. 2005.

Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in SLE patients. *Lupus.* 15:268-75, 2006.

Wozniacka A, Salamon M, Lesiak A, McCauliffe DP, Sysa-Jedrzejowska A. The dynamism of cutaneous lupus erythematosus: mild discoid lupus erythematosus evolving into SLE with SCLE and treatment-resistant lupus panniculitis. *Clin Rheumatol.* 2006.

McCauliffe DP, Sontheimer RD. Lupus erythematosus-specific cutaneous disorders. In: Wallace DJ and Hahn BH, editors. *Dubois' Lupus Erythematosus*, 6th edition. Philadelphia. Lippincott, Williams & Wilkins. 2007.

Wozniacka A, Lesiak A, McCauliffe DP, Sysa-Jedrzejowska A. Photoprotective properties of chloroquine phosphate. *J Eur Acad Dermatol Venereol.* 21:1133-4, 2007.

Wozniacka A, Robak E, McCauliffe DP, Sysa-Jedrzejowska A. The evolution of multiple forms of cutaneous lupus erythematosus in the same patient over time. *J Eur Acad Dermatol Venereol.* 22: 1237-9, 2008.

Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, McCauliffe DP, Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-1 β , IL-6 and TNF- α mRNA expression in the skin of systemic lupus erythematosus patients. *Br J Dermatol* 159:1124-30, 2008.

Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, Wóznicka A. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. *Lupus.* 19:683-8, 2010.

Salamon M, Omulecki A, McCauliffe DP, Woźniacka A. Psoriasis rupioides – a rare variant of a common disease. *Cutis* 88:135-7, 2011

Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C, Zabek J, Kontny E, McCauliffe DP, Wozniacka A. Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters. *Lupus* 21:477-84, 2012

Woźniacka A, Salamon M, McCauliffe DP, Sysa-Jędrzejowska A. Antinuclear antibodies in rosacea patients. *Postępy Postępy Dermatol Alergol* 30: 1–5, 2013.

Samochocki Z, Bogaczewicz J, Jeziorowska R, Sysa-Jedrzejowska A, Glinska O, Karczmarewicz E, McCauliffe DP, Wozniacka A. Vitamin D effects in atopic dermatitis, *J Am Acad Dermatol* 69: 238–44, 2013.

Samochocki Z, Bogaczewicz J, Sysa-Jedrzejowska A, McCauliffe DP, Kontny E, and Wozniacka A. Expression of vascular endothelial growth factor and other cytokines in atopic dermatitis, and correlation with clinical features. *Int J Dermatol* 55:e141-6, 2016.

Laboratory Investigation

Dermatology Foundation Career Development Award (1990-1992)

“The Role of Ro/SS-A Antigens in the Pathogenesis of the Lupus Erythematosus Specific Cutaneous Disorders, Subacute Cutaneous Lupus Erythematosus and Neonatal Lupus Erythematosus”

University of North Carolina Junior Faculty Development Award (1992)

“The Detection of Ro/SS-A Autoantibodies using Recombinant Ro/SS-A Proteins in ELISA and Immunoblot Analysis Compared to Conventional Techniques”

NIH First Award (1993-97)

“Pathogenic Role of Ro/SS-A Autoantigens in Skin Disease”

NIH Office of Research on Women’s Health Administrative Supplement to First Award, 1995-6

NIH R01 Award (1995-98) “Biologic Effects of DNA binding by 52 kD Ro/SS-A”

Visiting Physician Laboratory Fellowships

Jennifer Anne Yell, M.D. (1994-95)

Copeman Traveling Fellowship, Arthritis and Rheumatism Council (United Kingdom)
Department of Dermatology, Oxford Ratcliffe Hospital, Oxford, England

Localization of 52 and 60 kD Ro/SS-A antigens in human keratinocytes, as targets of autoimmune injury.

- 1) Yell JA, Wang L, Yin H, McCauliffe DP. The location of the 60 and 52 kD Ro (SS-A) antigens in human keratinocytes. **J Invest Dermatol** 104:641, 1995.
- 2) Yell, JA, Wang, L, Yin H, McCauliffe DP. 52 and 60 kD Ro/SS-A autoantigens have disparate intracellular locations in human keratinocytes. **Arthritis Rheum** 39:S181, 1996.
- 3) Yell JA, Wang L, Yin H, McCauliffe DP. Disparate locations of the 52 and 60 kD Ro/SS-A antigens in cultured human keratinocytes. **J Invest Dermatol** 107:622-626, 1996.

Anna Wozniacka, M.D. (1998-99)

Fulbright Scholarship

Department of Dermatology, Medical University of Lodz, Lodz, Poland

Chloroquine’s effects on mediators of inflammation and apoptosis in lupus versus normal keratinocytes.

- 1) Lopez M, Wozniacka A, McCauliffe DP. 52 Ro/SS-A protein resides along cytokeratins and other intermediate filaments. **Arthritis Rheum**, 2000
- 2) Wozniacka A, Carter A, McCauliffe DP. Mechanisms by which antimalarials may provide therapeutic benefit in cutaneous lupus erythematosus. **Lupus** 11:71-81, 2002.
- 3) Wozniacka A, Robak E, Sysa-Jedrzejowska A, McCauliffe DP. Pneumocystis carinii mimicking neonatal lupus erythematosus-related pneumonitis. Accepted for publication, **Pediatric Dermatology** 20:524-8, 2003.
- 4) McCauliffe DP, Sweeney A, Wozniacka A. 52 kD Ro/SS-A localizes to punctate structures in the cytoplasm of epithelial cells. Accepted for publication, **Cell Mol Biol Lett** 8:133-40, 2003.
- 5) Wozniacka A, Langer K, McCauliffe DP, Sysa-Jedrzejowska A, Langer M. Quantitative evaluation of 52 kD Ro/SS-A intracellular distribution in keratinocytes exposed to UVB radiation. **Optica Applicata** 34:77-85, 2004.
- 6) Wozniacka A, McCauliffe DP. Optimal use of antimalarials in treating cutaneous lupus erythematosus. **Am J Clin Dermatol**. 6:1-11, 2005.

MariCarmen Lopez, M.D. (1999-2000)

Rheumatology fellowship

Departments of Rheumatology Duke University & University of North Carolina

Antibody penetration into living cells as a mechanism of cell injury

Lopez M, Wozniacka A, McCauliffe DP. 52 Ro/SS-A protein resides along cytokeratins and other intermediate filaments. **Arthritis Rheum**, 2000